Document is current

Article History

Received: 19 March 2025

Accepted: 15 April 2025

First Online: 24 April 2025

Declarations

:

: The REFORM study received approval from both the Danish Data Protection Agency and the ethics committee of the Capital Region of Denmark (H-20033264 and H-20047793). All participants were given appropriate time to consider participation and provided written informed consent before undergoing any study-related procedures.

: Not applicable.

: WKK and HMA have each received a speaker’s honorarium from Pfizer and Lundbeck outside of the submitted work. RHC has received personal fees from Teva, the Lundbeck Foundation and research travel funding from Augustinus Fonden. TK and BNJ have no conflicts to report. OA is named inventor on patents covering suPAR owned by Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark and licensed to ViroGates A/S. MA is a consultant, speaker, or scientific advisor for AbbVie, Amgen, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva; a primary investigator for ongoing AbbVie and Pfizer trials; and is the past president of the International Headache Society. MA is supported through the Lundbeck Foundation Professor Grant (R310-2018-3711) and serves as associate editor of the Journal of Headache and Pain and associate editor of Brain. HA reports personal fees from AbbVie, Lundbeck, Pfizer, and Teva outside of the submitted work.